MSC Exosomes for Oxygen-Induced Thymic Dysfunction in Neonates

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Thymic dysfunction in newborns and neonates, caused by stress at birth or oxygen-induced involution, leads to impaired thymic architecture, reduced thymocyte counts, increased apoptosis, and impaired immune function, resulting in conditions such as autoimmune diseases and infections.

Innovation Solution

Administration of mesenchymal stem cell (MSC) exosomes, isolated from Warton's Jelly or bone marrow, to restore thymic architecture, increase thymocyte counts, reduce apoptosis, and promote medullary thymic epithelial cell maturation, thereby enhancing immune function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If oxygen is administered to treat respiratory conditions in newborns, then respiratory function is improved, but thymic involution occurs leading to impaired immune function

Engineering Contradiction:

Improverespiratory functionVSAvoidthymic involution

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

MSC exosomes are used as an intermediary substance to mediate between the harmful effect of oxygen therapy and the thymus. The exosomes carry protective signals that counteract oxygen-induced thymic damage without requiring direct intervention in the oxygen therapy itself, thus maintaining respiratory benefits while protecting immune function

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

MSC exosomes are administered to newborns before or during oxygen therapy to pre-establish protective mechanisms in the thymus. This preliminary anti-action prevents thymic involution from occurring in the first place, rather than treating it after damage has occurred

Inventive Principle:

Principle #9Preliminary anti-action

2Reliability

If MSC exosomes are administered to restore thymic architecture, then immune function is improved, but treatment complexity increases

Engineering Contradiction:

Improveimmune functionVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The therapeutic components are extracted from whole MSCs and isolated as exosomes. This extraction creates a simplified treatment product that can be administered without requiring live cell culture systems, reducing treatment complexity while maintaining immune restorative effects

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

MSC exosomes are used as a disposable therapeutic agent that can be produced, stored, and administered without requiring complex long-term maintenance systems. The exosomes deliver their therapeutic effect and are then cleared, avoiding the need for sustained complex treatment infrastructure

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentUS12521418B2Mesenchymal stromal cell exosomes and uses thereof

Publication Date: 2026.01.13 CHILDRENS MEDICAL CENT CORP

AI summary

Provided herein are methods of using mesenchymal stromal/stem cell (MCS) exosomes in the treatment of diseases associated with thymic dysfunction. In some embodiments, the MSC exosomes restore thymic architecture and development in a subject having thymic dysfunction (e.g., caused by exposure to hyperoxia). In some embodiments, the subject is a human subject (e.g., a human neonate).